Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Combination Devices--Application Landscape (Technical Insights)
Market Study
Published: June 2011
Pages: 68
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 4062.50 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Drug Delivery
This research service focuses on advances and the application landscape in the combination devices space pertaining to drug-device domain alone. It discusses in brief about the prospective technologies and on-going developments in those sectors. Drivers, challenges and their impact is featured with a broad outlook on the global technology development and adoption footprint. Scenario modelling and strategic conclusions are featured and a comparison is drawn among the different technologies from among their different pathologic areas. The research service ends showcasing patents, patent analysis and contact details.
Medical Device Application Landscape Influenced by the Adoption of Emerging Drug-Device Combinations
Manufacturers to Collaborate with Large Healthcare Companies to Commercialize Their Devices
Minimally invasive combination drug-device approaches are emerging as viable treatment options that can extend survival, decrease organ toxicity, and improve the quality of life of patients with severe indications. Novel developments in technology and supporting clinical data have made a strong case for the adoption of the combination drug-device approach for pathology research. The rapid advances in image-guidance technologies have also made precise and effective application of combination drug-device approach a clinically feasible option. Drug delivery systems have always comprised a vast segment of biomaterials R&D, and this branch of technology development has got a boost from the demand for smart and biocompatible drug delivery devices. Despite its nascence, drug-device combination is demonstrating its efficiency in targeted drug delivery through the adoption of popular approaches involving nanotechnology, photodynamic therapy, and antimicrobial implants, apart from tablets and pills. Combination devices, with their unique construction and drug release profiles, have changed the way drugs are administered. A targeted approach enables the delivery of higher therapeutic dosages while minimizing adverse side effects. It offers greater control over toxicity and bioavailability of dose in addition to continuous therapeutic drug release over prolonged periods.
Through combination techniques, silica nanorattles as drug carriers of anti-tumor drug docetaxel can now be used for sustained and pH-sensitive drug release. Similarly, conventional polymers can be incorporated with nanoparticles to form nano composites for achieving targeted drug delivery. Among the diverse existing platforms, nano-biomaterials under investigation for cancer treatment have garnered significant attention due to their unique features. ?Drug delivery devices are inherently complex systems that require the integration of the drug substance, formulation, container closure, and the device for optimum product functionality,? says the analyst of this research. ?Nowadays, patient-driven delivery devices incorporating a biologics portfolio are emerging as better alternatives to single-entity devices for providing enhanced therapeutic advantages.? The detection of cancer indications is one of the most important areas of pathology influenced by the integration of combination device. Cancer treatment needs to address the two formidable challenges of tumor heterogeneity and adaptive resistance. As a platform technology, the combination of multiple parameters has the remarkable ability to target tumor markers and deliver agents simultaneously for synergy in addressing the dual challenges of cancer heterogeneity and adaptive resistance.
Customer preference for miniaturized platforms is compelling combination device manufacturers to create implantable devices for diagnostic and therapeutic delivery at the micro to nano levels. As more companies begin to adopt the open innovation model for developing products, inventions will pick up pace steadily across combining drugs, devices, and biologics. To ensure the speed does not slacken, manufacturers have to guard against suboptimal drug products, as the wrong drug mixture can lead to harmful side effects. A poor choice of biomaterials can cause the coating to flake off or too much drug being deposited in the body. Technology developers are still unable to achieve the desired efficacy levels for the therapy sought. Further, they often lack the funds to take the product to the commercialization phase. Therefore, companies often license their products to a large device manufacturer or collaborate with a pharmaceutical company to get the product to the market. ?As combination devices is a relatively new concept within the medical devices sector, technology licensing, spin-off companies, and research groups are normally the prevailing model for commercialization, both for emerging companies as well as major participants,? notes the analyst.
Application Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Diagnostic tools
Bacteriophages
Antibiotics
Manufacturers to Collaborate with Large Healthcare Companies to Commercialize Their Devices
Minimally invasive combination drug-device approaches are emerging as viable treatment options that can extend survival, decrease organ toxicity, and improve the quality of life of patients with severe indications. Novel developments in technology and supporting clinical data have made a strong case for the adoption of the combination drug-device approach for pathology research. The rapid advances in image-guidance technologies have also made precise and effective application of combination drug-device approach a clinically feasible option. Drug delivery systems have always comprised a vast segment of biomaterials R&D, and this branch of technology development has got a boost from the demand for smart and biocompatible drug delivery devices. Despite its nascence, drug-device combination is demonstrating its efficiency in targeted drug delivery through the adoption of popular approaches involving nanotechnology, photodynamic therapy, and antimicrobial implants, apart from tablets and pills. Combination devices, with their unique construction and drug release profiles, have changed the way drugs are administered. A targeted approach enables the delivery of higher therapeutic dosages while minimizing adverse side effects. It offers greater control over toxicity and bioavailability of dose in addition to continuous therapeutic drug release over prolonged periods.
Through combination techniques, silica nanorattles as drug carriers of anti-tumor drug docetaxel can now be used for sustained and pH-sensitive drug release. Similarly, conventional polymers can be incorporated with nanoparticles to form nano composites for achieving targeted drug delivery. Among the diverse existing platforms, nano-biomaterials under investigation for cancer treatment have garnered significant attention due to their unique features. ?Drug delivery devices are inherently complex systems that require the integration of the drug substance, formulation, container closure, and the device for optimum product functionality,? says the analyst of this research. ?Nowadays, patient-driven delivery devices incorporating a biologics portfolio are emerging as better alternatives to single-entity devices for providing enhanced therapeutic advantages.? The detection of cancer indications is one of the most important areas of pathology influenced by the integration of combination device. Cancer treatment needs to address the two formidable challenges of tumor heterogeneity and adaptive resistance. As a platform technology, the combination of multiple parameters has the remarkable ability to target tumor markers and deliver agents simultaneously for synergy in addressing the dual challenges of cancer heterogeneity and adaptive resistance.
Customer preference for miniaturized platforms is compelling combination device manufacturers to create implantable devices for diagnostic and therapeutic delivery at the micro to nano levels. As more companies begin to adopt the open innovation model for developing products, inventions will pick up pace steadily across combining drugs, devices, and biologics. To ensure the speed does not slacken, manufacturers have to guard against suboptimal drug products, as the wrong drug mixture can lead to harmful side effects. A poor choice of biomaterials can cause the coating to flake off or too much drug being deposited in the body. Technology developers are still unable to achieve the desired efficacy levels for the therapy sought. Further, they often lack the funds to take the product to the commercialization phase. Therefore, companies often license their products to a large device manufacturer or collaborate with a pharmaceutical company to get the product to the market. ?As combination devices is a relatively new concept within the medical devices sector, technology licensing, spin-off companies, and research groups are normally the prevailing model for commercialization, both for emerging companies as well as major participants,? notes the analyst.
Application Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Diagnostic tools
Bacteriophages
Antibiotics